Post-Traumatic Stress Disorder: Epidemiology Forecast to 2028

2019-06-13
Price :
Published : Jun-2019
No. of Pages : 26

Post-Traumatic Stress Disorder: Epidemiology Forecast to 2028

Summary

Post-Traumatic Stress Disorder (PTSD) is a psychiatric disorder that can occur in people who have experienced or witnessed a traumatic event such as a natural disaster, a serious accident, a terrorist act, war/combat, rape, or other violent personal assault (American Psychiatric Association, 2018). PTSD affects as many as one in four people who experience traumatic events, and contributes to marked functional disability, health impairment, and social dysfunction. People with PTSD may relive the event via intrusive memories, flashbacks, and nightmares; avoid anything that reminds them of the trauma; and have anxious feelings they didn’t have before (North, Hong and Downs, 2018).

GlobalData epidemiologists utilized national databases and robust peer-reviewed journal articles to build the forecast for the 12-month total prevalent cases of PTSD in the 7MM. GlobalData epidemiologists applied country-specific 12-month total prevalent cases of PTSD, wherever available, to each country’s population to obtain the number of estimated 12-month total prevalent cases.

The following data describes epidemiology of PTSD. GlobalData epidemiologists forecast an increase in the 12-month total prevalent cases of PTSD in the 7MM from 17,115,231 cases in 2018 to 17,846,569 cases in 2028, at an Annual Growth Rate (AGR) of 0.43% per year during the forecast period. The US will have the highest number of 12-month total prevalent cases of PTSD among the 7MM, while Japan will have the lowest.

Scope

– The Post-traumatic stress disorder Epidemiology Report provides an overview of the risk factors and global trends of Post-traumatic stress disorder (PTSD) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
– The report includes a 10-year epidemiological forecast for the 12-month total prevalent cases of PTSD segmented by sex, and age (for ages 18 years and older) in these markets. The 12-month total prevalent cases of PTSD are further segmented by onset of disease (acute and chronic, and delayed onset).
– The PTSD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
– The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The PTSD Epidemiology report will allow you to –
– Develop business strategies by understanding the trends shaping and driving the global PTSD market.
– Quantify patient populations in the global PTSD market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for PTSD therapeutics in each of the markets covered.
– Understand magnitude of PTSD population by the onset of disease.

Filed in: Pharmaceutical, Therapeutics
Publisher : GlobalData
More Reports
Title Price Buy Now

B-Cell Non-Hodgkin’s Lymphoma: Epidemiology Forecast to 2027

B-Cell Non-Hodgkin's Lymphoma: Epidemiology Forecast to 2027 Summary Non-Hodgkin's lymphoma (NHL) refers to a group of cancers that develop in the lymphatic system. In NHL, the patient's immune system is affected by the uncontrollable growth of malignant white blood cells, resulting in the body's inability to fight infections and other diseases. NHL accounts for 90% of all malignant lymphomas. NHL is one of the most prevalent hematologic cancers in adults and is more commonly diagnosed in developed countries. B-cell lymphomas are the most common form of NHL diagnosed in developed countries, making up approximately 80-85% of NHL cases in the US. GlobalData epidemiologists used age- and sex-specific diagnosed incidence and prevalence rates to forecast the diagnosed incident and prevalent ......
$3995

Partnerships, Licensing, Investments and M&A Deals and Trends for April 2019 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for April 2019 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for April 2019 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in April 2019. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides......
$1000

Digital Therapeutics and Their Impact on Healthcare

Digital Therapeutics and Their Impact on Healthcare Summary Due to increasing levels in healthcare spending combined with declining R&D returns, digital therapeutics (DTx) represent a new way of treatment in which digital systems are used as regulatory?approved, to treat medical conditions as prescribed therapeutic interventions. There is a growing number of DTx developed on the market today as well as pipeline products in development following internationally-recognized, quality, design and manufacturing standards. DTx will provide a new approach to treatment and disease management in which patients have the possibility to learn more about their conditions and treatment options and this will lead to manage their own health and disease conditions. This report provides an overview of cur......
$7995

Allergic Diseases: Pipeline Offers Novel Approaches to Treat Increasingly Prevalent Conditions, with Strong Presence of Cytokine Mediators Among First-in-Class Products

Allergic Diseases: Pipeline Offers Novel Approaches to Treat Increasingly Prevalent Conditions, with Strong Presence of Cytokine Mediators Among First-in-Class Products Summary An allergy or allergic disease is a condition that arises from an adverse reaction to an exogenous antigen, a substance that invokes an immunological response. These conditions are extremely common. The number of people diagnosed with allergic diseases is rising rapidly on a global scale, which is attributable to factors such as population growth and increased urbanization and pollution. In addition, for a minority of these patients, allergic reactions can be severe, debilitating, or even life-threatening. Despite this high disease burden, treatment options are limited for many conditions and patients often recei......
$6995

Pharmaceutical & Healthcare Quarterly Deals Analysis M&A and Investment Trends – Q1 2019

Pharmaceutical & Healthcare Quarterly Deals Analysis M&A and Investment Trends - Q1 2019 Summary GlobalData's "Pharmaceutical & Healthcare Quarterly Deals Analysis M&A and Investment Trends - Q1 2019", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q1 2019. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information o......
$1500

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Italy

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Italy Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Italy". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Italy. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Italy. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by ......
$1995

Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2018. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on th......
$3500

Parkinson’s Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects

Parkinson's Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects Summary Parkinson's disease (PD), a progressive neurological disorder that affects movement control, is associated with considerable quality of life impairments and burden of care, particularly in the advanced disease stages. Cognitive and behavioral complications of PD are common. PD-associated dementia and PD-associated psychosis are both highly prevalent and associated with a large disease burden. There is a pressing unmet need within PD, PD-associated dementia, and PD-associated psychosis for more effective disease-modifying pharmacotherapies. Although current therapies can provide patients with symptomatic relie......
$6995

Dermatitis (Eczema) Global Clinical Trials Review, H1, 2019

Dermatitis (Eczema) Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Dermatitis (Eczema) Global Clinical Trials Review, H1, 2019" provides an overview of Dermatitis (Eczema) clinical trials scenario. This report provides top line data relating to the clinical trials on Dermatitis (Eczema). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical t......
$2500

Dupuytren Contracture Global Clinical Trials Review, H1, 2019

Dupuytren Contracture Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Dupuytren Contracture Global Clinical Trials Review, H1, 2019" provides an overview of Dupuytren Contracture clinical trials scenario. This report provides top line data relating to the clinical trials on Dupuytren Contracture. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Cl......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy